Chemical castration improves responses to radiotherapy in prostate cancer, but the mechanism is unknown. We hypothesized that this radiosensitization is caused by castration-mediated down-regulation of nonhomologous end joining (NHEJ) repair of DNA double-strand breaks (DSBs). To test this, we enrolled 48 patients with localized prostate cancer in two arms of the study: either radiotherapy first or radiotherapy after neoadjuvant castration treatment. We biopsied patients at diagnosis and before and after castration and radiotherapy treatments to monitor androgen receptor, NHEJ, and DSB repair in verified cancer tissue. We show that patients receiving neoadjuvant castration treatment before radiotherapy had reduced amounts of the NHEJ protein Ku70, impaired radiotherapy-induced NHEJ activity, and higher amounts of unrepaired DSBs, measured by g-H2AX foci in cancer tissues. This study demonstrates that chemical castration impairs NHEJ activity in prostate cancer tissue, explaining the improved response of patients with prostate cancer to radiotherapy after chemical castration.
INTRODUCTION
Despite the technical improvements achieved in radiotherapy, the final outcome of this single treatment modality is still uncertain, with a high risk of recurrence among patients with unfavorable prognostic risk factors (1) (2) (3) (4) . However, several randomized clinical trials have revealed that the addition of neoadjuvant castration improves long-term local control and survival (5) (6) (7) (8) (9) (10) .
Thus, the combination of neoadjuvant castration with radiotherapy has currently become, in many treatment centers, the standard of care for patients with intermediate-and high-risk prostate cancer. However, timing and duration of this castration in combination with radiotherapy need to be better defined (11) . A better understanding of the biological mechanism of action is essential for the optimization of treatment and the development of new therapeutic methods.
Radiotherapy induces various forms of DNA damage, the most important and toxic lesion being DNA double-strand breaks (DSBs). Nonhomologous end joining (NHEJ), catalyzed by DNA-dependent protein kinase (DNA-PK), is the most effective DNA repair mechanism for DSBs and works during all phases of the cell cycle (12, 13) . In NHEJ, the DSB ends are bound by the abundant Ku70/80 heterodimer, which in turn attracts the catalytic subunit DNA-PKcs, that orchestrates the end-joining process and phosphorylates itself (on Ser 2056 ) and other proteins, such as ligase IV and XRCC4, for final rejoining and ligation (14, 15) . Using biopsies from patients with prostate cancer, we previously demonstrated that castration in a neoadjuvant setting (that is, therapy given before definitive local treatment with curative intent) decreases the expression of Ku70 (16) , which could potentially influence NHEJ and explain improved survival after radiotherapy. These findings have been confirmed by two other studies demonstrating both in vitro and in vivo with mouse xenografts that androgen receptor regulates the transcription of DNA repair genes (17, 18) . Here, we test the hypothesis that neoadjuvant castration reduces the DNA repair capacity of the NHEJ repair pathway in prostate cancer cells after radiotherapy.
RESULTS

Up-regulation of Ku70 by radiotherapy is prevented by neoadjuvant castration
In a previous study, we showed that the Ku70 protein interacts with androgen receptor and the levels of Ku70 protein were reduced after castration in prostate cancer cells (16) . Because Ku70 is a vital component of NHEJ, we suggested that impaired DSB repair could potentially be the mechanistic explanation for the increased radiosensitivity subsequent to castration. However, androgen receptor regulates numerous genes and the decreased levels of Ku70 or other repair proteins may not influence NHEJ activity and DSB repair in cells. To test this hypothesis directly, we recruited 48 patients with prostate cancer into a two-arm prospective study (Fig. 1A) and used a computational approach to measure responses within individual cells in the tissue (Fig. 1B) . In the first arm, we performed neoadjuvant castration 5 days before radiotherapy, whereas in the second arm, we prescribed radiotherapy 5 days before castration. We obtained tumor biopsies at diagnosis and before and after treatment and analyzed DSB repair. In both arms, castration treatment either before or after radiotherapy resulted in a similar decrease in serum prostate-specific antigen (PSA) (P < 0.001; table S1), and median testosterone levels in serum were 0.7 nM in both arms. Serum testosterone <1.7 nM was not achieved in two patients in arm 1 and in four patients in arm 2 after 8 weeks of chemical castration, although serum PSA decreased markedly. These patients were still included in our study and statistical analysis.
We determined cytosolic and intranuclear Ku70 protein using immunofluorescence and observed no difference between patient arms at diagnosis. In both arms, castration decreased Ku70 levels to the same extent regardless of previous radiotherapy treatment (P < 0.01) (Fig. 2, A and B ).
There was a statistically significant increase in the mean intensity of intranuclear Ku70 after 5 × 2 Gy radiotherapy fractions (P = 0.014). We interpret this as up-regulation of Ku70, and likely other NHEJ proteins, after 5 days of radiotherapy treatment-induced DSB repair. No such up-regulation of Ku70 was found in prostate cancer patients receiving chemical castration alone (Fig. 2B) .
Intranuclear levels of androgen receptor were determined in prostate tumor material from all patient biopsies. As expected, no difference was observed between the arms before castration. It has previously been reported that androgen receptor activity is increased after radiotherapy. Figure 2A shows more distinct staining for androgen receptor after radiotherapy but no statistically significant increase in intranuclear androgen receptor (Fig. 2B) . No difference was observed in the pretreatment mean intensity of intranuclear androgen receptor between arm 1 and arm 2 (P = 0.3) (Fig. 2B) . As expected, intranuclear androgen receptor staining intensity decreased after castration (Fig. 2B) . Using Spearman's rho rank correlation test (r), we observed in both arms a significant correlation between pretreatment mean staining intensity of intranuclear Ku70 and androgen receptor (r = 0.62, P < 0.001), and in arm 1 after castration (r = 0.65, P < 0.001) (Fig. 2, C and D) . To investigate whether the decrease in nuclear androgen receptor after castration correlated with a decrease in nuclear Ku70, we measured the correlation between the induced changes in those proteins. The postcastration decrease in nuclear androgen receptor was accompanied by a corresponding decrease in intranuclear Ku70. In arm 1, there was a significant correlation after castration (r = 0.52, P < 0.001) and after combined castration and radiotherapy (r = 0.33, P = 0.001). In arm 2, there was a significant correlation after radiotherapy (r = 0.64, P < 0.001) and after subsequent castration (r = 0.53, P < 0.001).
The residual radiation-induced DSBs increase after castration Next, we wanted to assess if neoadjuvant castration affected DSB repair. To assess the extent of DNA damage after castration alone, or castration plus radiotherapy, we took biopsies 3 hours after completion of radiotherapy to be stained with antibodies against p53-binding protein 1 (53BP1) and phosphorylated H2AX histone (g-H2AX). Both 53BP1 and g-H2AX are involved in the early steps of the DNA damage response and are commonly used as markers of DSBs (19) . Immunofluorescence staining with antibodies against 53BP1 and g-H2AX was quantified in prostate cancer tissue in corresponding paired slides (Fig. 3A) . Radiotherapy in both arms induced a statistically significant increase in both g-H2AX and 53BP1 foci (P < 0.001), and there was colocalization between the g-H2AX and 53BP1 foci (Fig. 3B and fig. S1 ). Although castration alone did not increase the amount of DSBs (Fig. 3C) , we observed that castration alone induced a significant reduction in the mean staining intensity of intranuclear 53BP1 in both arms (P < 0.05, Fig. 3D ), indicating that the androgen receptor itself may be involved in 53BP1 expression.
We observed a clear increase in radiotherapy-induced g-H2AX in arm 1 with neoadjuvant castration treatment (P < 0.05), demonstrating that the number of toxic DSBs was increased in patients receiving neoadjuvant castration (Fig. 3C) . Hence, we predicted that the remaining DSBs would be more lethal to the prostate cancer cells in arm 1, translating to a better overall outcome among prostate cancer patients after radiotherapy. We did not observe a statistically significant difference in staining for 53BP1 foci between the two arms, which is likely due to the fact that 53BP1 appears to be down-regulated by castration itself, leading to reduced foci intensity and thereby an underestimation of the number of foci (Fig. 3C ).
Neoadjuvant castration impairs NHEJ activity
Here, we report that a decrease in Ku70 after castration is correlated with an increase in residual DSBs in prostate cancer tissue, suggesting that lost NHEJ activity may explain decreased DSB repair and improved prostate cancer patient survival after radiotherapy. Next, we wanted to determine whether this hypothesis is correct so we measured NHEJ activity in prostate cancer tissue. The Ku70/80 heterodimer recruits DNA-PK to DNA ends, activating its kinase activity, which results in DNA-PK autophosphorylation on Ser
2056
, which is required to complete NHEJ (20) . Here, we used a phosphorylated DNA-PKcs-specific antibody recognizing phosphorylated S2056 (pS2056) on DNA-PK, as a method of measuring ongoing NHEJ repair (Fig. 4A) .
DNA-PK phosphorylation was low before treatment and after castration (Fig. 4C ). After radiotherapy, we observed a robust increase in Areas encircled with white lines were used for measurements of staining intensity inside the nuclei and were extracted by using the DNA signal as a mask marker for nuclei. The extracted nuclei were processed with an algorithm to exclude stromal cells. Background measurements were performed in the 5-mm-wide area outside the nuclei depicted as blue in the figure. Between the nucleus and the blue area, there was a 1-mm-wide strip that was not measured to avoid any nuclear signal in the background measurements. (C) Original images were used for classification of Ki67-positive cells. Extraction of nuclei was done as described above. A threshold was applied to the Ki67 staining intensity signal. The areas with a signal above the threshold were used to calculate the fraction of Ki67-positive cells. (D) Original images were used for DSB foci (53BP1 and g-H2AX) measurements. Lower right panel shows the same images after computer processing. Extraction of nuclei was done as described above. To extract the foci, an algorithm that considers the local changes in staining intensity was used. Scale bars, 50 mm.
the mean staining intensity of nuclear phosphorylated DNA-PKcs (P = 0.01) (Fig. 4 , B and C), demonstrating strong activation of DNA-PK-mediated NHEJ repair of DSBs. In contrast, neoadjuvant castration treatment before radiotherapy completely abolished radiotherapy-induced phosphorylated DNA-PKcs in arm 1. Because the biopsies after radiotherapy and castration in arm 2 were taken 8 weeks after the last fraction of radiation, the subsequent phosphorylation of DNA-PKcs dropped below background levels (35%, P < 0.001) (Fig. 4C ). NHEJ and homologous recombination are two major DNA repair pathways that mediate DSB repair. NHEJ is the most efficient DSB repair pathway and works in all cell cycle phases (21, 22) , whereas homologous recombination is a slow multistep process that requires several proteins and operates exclusively during the S and G 2 phases of the cell cycle (23) . Next, we tested the possibility that homologous recombination could play a major role in repair of DSBs induced during radiotherapy.
Using the Ki67 protein as a marker of proliferative activity (cells in S and G 2 phases), we assessed how castration and/ or radiotherapy affected prostate cancer cells during the cell cycle. The number of proliferating cells according to Ki67 staining was 7% in both arms before castration and radiotherapy ( fig. S2 ). Castration treatment resulted in a decrease to about 1.5% Ki67-positive cells in both arms, and 5 days of radiotherapy treatment resulted in a marked reduction in Ki67-positive cells in both arms to about 0.5% (P < 0.001 for both) ( fig. S2 ). These results suggest that the prostate cancer cells entered into cell cycle arrest (G 0 ) after both castration and radiotherapy treatment and therefore relied solely on NHEJ for repair of radiotherapy-induced DSBs.
DISCUSSION
Prostate cancer is the most common type of cancer in many countries, and the incidence is increasing worldwide. It is well established that the combination of chemical castration and radiotherapy improves survival of patients with localized intermediate-and high-risk prostate cancer (5) (6) (7) (8) (9) (10) . Understanding the underlying molecular mechanism explaining how neoadjuvant castration improves overall responses to radiotherapy is critical to rationally improve clinical protocols to increase overall patient survival. Previously, we reported a reduction in the Ku70 protein in prostate cancer tissue after castration (16) , suggesting that NHEJ may be affected by castration. Preclinical results obtained using the LNCaP prostate cancer cell line showed that androgen deprivation therapy decreased NHEJ (17) and that androgen receptor expression induced and promoted DNA-PKcs expression and activity (18) . However, these results were complicated by the fact that DNA-PKcs also serves as a cofactor in androgen receptor-mediated transcription (18, 24) . Hence, the role of DNA-PK and androgen receptor is complex and the situation in prostate cancer patients may differ from the behavior of prostate cancer cell lines grown in vitro in the absence of a functional tumor microenvironment. Here, we demonstrate in prostate tumor tissue from patients that the decrease in Ku70 after chemical castration correlated with an increase in residual radiotherapy-induced DSBs, indicating a failure in NHEJ repair. Impaired activation of NHEJ was also supported by the low staining intensity of DNA-PK (pS2056) in prostate tumor tissue shown after combined castration and radiotherapy as compared with radiotherapy alone. Because the specificity of the DNA-PK (pS2056) antibody has not been validated in human formalin-fixed, paraffin-embedded samples, we cannot exclude that castration impaired other radiotherapy-induced phosphorylation cascades, such as the ATM (ataxia-telangiectasia mutated) signaling pathway. Previous in vitro studies only showed marginal reduction in NHEJ repair (17) . However, in the current study, the decrease in Ku70 after castration was more robust with a 30% reduction in Ku70 compared to before castration. Together, these data suggest that androgen receptor regulation of NHEJ is more rigorous in prostate cancer tissue from patients than observed in cell lines in vitro. Also, this suggests that NHEJ proteins other than Ku70 may be regulated by androgen receptor to maintain proficient NHEJ. Homologous recombination repair of radiotherapyinduced DSBs appears not to be operating in prostate cancer tissue because there are too few (<1%) cells in the S or G 2 phases of the cell cycle during radiotherapy, when homologous recombination is active. An interesting observation is that the overall staining intensity for 53BP1 was reduced after castration. These data suggest that the DNA damage response is affected by castration in prostate cancer patients, which potentially could be exploited therapeutically in the future by combining DNA repair inhibitors.
Chemical castration affects only the androgen-synthesizing testicular Leydig cells, which are under the control of the pituitary-gonadal axis. After castration, serum androgen decreases by 90 to 95%, leaving 5 to 10% of androgen produced by the adrenal glands (8) . Emerging evidence suggests that residual androgen production by the adrenal glands and de novo steroid synthesis from cholesterol or progesterone precursors eventually lead to continued prostate cancer growth. Abiraterone and enzalutamide prevent intratumoral androgen production by targeting androgen biosynthesis (through CYP17A) (25) or inhibiting androgen receptor nuclear translocation (26) , respectively. Enzalutamide and ARN-509 (another antiandrogen drug) down-regulate NHEJ and improve radiosensitivity in preclinical cancer models (17, 18) . Clinical trials have shown that the use of second-generation drugs such as abiraterone and enzalutamide improves overall survival of patients with castration-resistant prostate cancer (25, 26) . Because castration alone does not suppress androgen-regulated genes sufficiently, the second-generation drugs may be efficacious because they suppress these genes, potentially leading to further impairment of NHEJ in a neoadjuvant setting and improving radiosensitivity (27) . A remaining open question is whether prostate cancer relapse after castration plus radiotherapy is due to insufficient androgen depletion after castration.
A limitation of our study is that we cannot describe in detail how the androgen receptor mediates NHEJ repair, for example, if it is solely through transcriptional regulation of proteins involved in NHEJ or if there is a more direct role for androgen receptor in NHEJ. Such questions are more difficult to resolve with patient material and are better addressed in vitro. Our current study is focused on NHEJ repair, but it is possible that androgen receptor also mediates other repair or signaling pathways that are important for sensitizing prostate cancer cells to radiotherapy. Fig. 3 . Effects of castration and radiotherapy on nuclear staining for 53BP1 and g-H2AX. Determination of nuclear 53BP1 and g-H2AX in prostate cancer tissue before treatment (Baseline) and after different treatment modalities in arms 1 and 2. (A) Different sections of prostate cancer biopsies are shown, and each biopsy is sectioned and stained. The first section was stained with H&E to identify cancer areas. A corresponding adjacent section obtained from the same biopsy was stained with anti-g-H2AX mouse monoclonal antibody (green) and anti-53BP1 rabbit polyclonal antibody (red). The DNA was costained with TO-PRO-3 (blue). Upper sections were from a patient in arm 1; the upper panel was before treatment (baseline), middle panel was after castration, and lower panel was after castration and radiotherapy. Lower sections were from a patient in arm 2; the upper panel was before treatment (baseline), middle panel was after radiotherapy, and lower panel was after radiotherapy and castration. Scale bars, 100 mm. We have shown that the improved survival of prostate cancer patients achieved by combined castration and radiotherapy may be explained by impaired NHEJ repair of DSBs. This results in an increase in radiotherapy-induced DSBs, leading to apoptosis of prostate cancer cells. Given that radiosensitization of prostate cancer tissue is optimally achieved after a combination of radiotherapy and castration, we predict even better radiosensitization of prostate tumor tissue that expresses more androgen-sensitive androgen receptor.
MATERIALS AND METHODS
Study design
Patients with localized, that is, nonmetastatic, prostate cancer, eligible for curative radiotherapy, were enrolled in the study. Before inclusion, patients underwent examinations with bone scans and complementary imaging with computerized tomography or magnetic resonance imaging to exclude distant metastases. After completion of written informed consent, the patients were allocated to one of the two study arms. After signing the informed consent, 3 patients in arm 1 and 1 patient in arm 2 refused further biopsies, so there remained 25 participants in arm 1 and 23 in arm 2 who were eligible for this study. Patient characteristics are summarized in table S1. The regional ethics committee of Uppsala University granted ethical approval, EPN Dnr 2011:066. In arm 1, the patients received neoadjuvant chemical castration with leuprorelin, a gonadotropin-releasing hormone analog, followed by external beam radiotherapy in daily 2 Gy fractions to a total dose of 78 Gy. In arm 2, the patients first received radiotherapy in 2 Gy daily fractions for five consecutive days followed by neoadjuvant leuprorelin and then an equivalent higher radiotherapy dose to a total of 82 Gy (see Fig. 1A ). Before treatment, prostate needle core biopsy specimens were obtained from all patients. In arm 1, a second biopsy was taken 8 weeks after the leuprorelin injection, that is, before radiotherapy was started, and a third biopsy was taken about 3 hours after the fifth radiotherapy fraction. In arm 2, a second biopsy was taken about 3 hours after the fifth radiotherapy fraction, that is, before hormone treatment was initiated, and a third biopsy was taken 8 weeks after the administration of leuprorelin (Fig. 1A) .
Histology and immunofluorescence
All prostate tissue needle biopsy specimens were embedded in paraffin, sectioned, and stained with H&E. In all specimens, the cancer areas were assessed according to the Gleason system (28) and marked by a uropathologist. Two cancer-rich specimens from each batch of biopsies were further sectioned for immunofluorescence analysis. These sections were deparaffinized and rehydrated before antigen retrieval with R-Buffer A (Electron Microscopy Sciences) in a pressure cooker. After blocking with 2% bovine serum albumin, the sections were incubated with different primary antibodies at 4°C overnight. Extensive rinsing was performed once; the sections were incubated with the secondary antibodies donkey anti-mouse immunoglobulin G (IgG)-Alexa Fluor 488 (1:500; Molecular Probes) and donkey anti-rabbit IgG-Alexa Fluor 555 (1:500; Molecular Probes) for 1 hour at room temperature. DNA was counterstained with TO-PRO-3 iodide (Molecular Probes), and slides were mounted with ProLong Gold (Molecular Probes). Slides were stained with antibodies against (i) androgen receptor (1:500, N-20, sc-816, Santa Cruz Biotechnology) and Ku70 (1:500, E-5, sc-17789, Santa Cruz Biotechnology), (ii) 53BP1 (1:1000, Bethyl Laboratories) and g-H2AX (1:1000, 3F2, Abcam), (iii) phosphorylated DNA-PKcs alone (1:750, S2056, Abcam), or (iv) Ki67 alone (1:200, MIB-1, Dako). Images from a tumor area with a good immunofluorescence signal were selected from each biopsy. The corresponding areas in the H&E-stained section were identified for histological verification of the tumor area. In slides stained for Ku70, androgen receptor, Ki67, or phosphorylated DNA-PKcs, two areas from each slide containing 300 to 600 cells were chosen for analyses. TO-PRO-3 was used as a DNA marker.
All images were analyzed, with respect to medium staining intensity inside the nuclei and in the cytoplasm. The nuclear area was defined by the TO-PRO-3 signal and the cytoplasmic area as a 5-mm extension outside the nuclear area ( Fig. 2A) . For those proteins with exclusively nuclear localization (53BP1 and phosphorylated DNA-PKcs), the intensity in the cytoplasm was considered as background. For other proteins, with both nuclear and cytoplasmic localization (Ku70 and androgen receptor), staining intensity values are presented without background subtraction (Fig. 1B) . The measurement of the number of Ki67-positive cells was performed using a threshold for Ki67 intensity in the nucleus to distinguish positive from negative cells (Fig. 1C) . For those markers that form foci, the number and area of foci per DNA unit were measured (Fig. 1D) . All measurements were performed using an in-house written program for National Institutes of Health (NIH) ImageJ (29) . Fluorescence images were obtained with either a Zeiss LSM 510 inverted confocal microscope or a Zeiss LSM 780 inverted confocal microscope, using a Plan-Apochromat 40×/NA (numerical aperture) 1.2 objective. Through-focus maximum projection images were acquired from optical sections 0.5 mm apart and with a section thickness of 1.0 mm. H&E-stained images were obtained with a Leica scan system.
Statistical analysis
Nonparametric test methods were applied. Related outcomes after different treatments within each arm were compared using the Wilcoxon signedrank test. Unrelated outcomes between the study's two arms were compared using the Mann-Whitney U test. Correlation analysis was conducted using Spearman's rho rank correlation test (r). All statistical tests were two-tailed with significance established at P < 0.05. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 21.0.
SUPPLEMENTARY MATERIALS
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